Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases

Pigment Cell and Melanoma Research

Volumn 29, Issue 1, 2016, Pages 92-100

  Seifert, Heike ^a   Hirata, Eishu ^b,c   Gore, Martin ^a   Khabra, Komel ^a   Messiou, Christina ^a   Larkin, James ^a   Sahai, Erik ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

BRAF mutant; Brain metastases; Central nervous system metastases; Metastatic melanoma; Resistance; Vemurafenib

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; B RAF KINASE; B RAF KINASE INHIBITOR; CYANOCOBALAMIN; DABRAFENIB; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C; VEMURAFENIB; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADULT; AGED; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER REGRESSION; CANCER RESISTANCE; CELL DEATH; CELL KILLING; CELL VIABILITY; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IN VITRO STUDY; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MELANOMA CELL; METASTATIC MELANOMA; NONHUMAN; RAT; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TREATMENT RESPONSE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; MALE; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; SECONDARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CELL DEATH; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; ORGAN SPECIFICITY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; YOUNG ADULT;

EID: 84951568398     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12424     Document Type: Article

References (29)

1. COMBI-MB (2015). https://clinicaltrials.gov/ct2/show/NCT02039947.
2. Azer, M.W., Menzies, A.M., Haydu, L.E., Kefford, R.F., and Long, G.V. (2014). Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib. Cancer 120, 530-536.
3. Bilic, E., Rudan, I., Kusec, V., Zurak, N., Delimar, D., and Zagar, M. (2006). Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. Eur. J. Neurol. 13, 1340-1345.
4. Bucheit, A.D., and Davies, M.A. (2014). Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem. Pharmacol. 87, 381-389.
5. Carlino, M.S., Todd, J.R., Gowrishankar, K. et al. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol. 8, 544-554.
6. Chan, M.M., Haydu, L.E., Menzies, A.M., Azer, M.W., Klein, O., Lyle, M., Clements, A., Guminski, A., Kefford, R.F., and Long, G.V. (2014). The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer 120, 3142-3153.
7. Chen, G., Chakravarti, N., Aardalen, K. et al. (2014). Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin. Cancer Res. 20, 5537-5546.
8. Dhomen, N., Reis-Filho, J.S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C., and Marais, R. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294-303.
9. Dummer, R., Goldinger, S.M., Turtschi, C.P., Eggmann, N.B., Michielin, O., Mitchell, L., Veronese, L., Hilfiker, P.R., Felderer, L., and Rinderknecht, J.D. (2014). Vemurafenib in patients with BRAF mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur. J. Cancer 50, 611-621.
10. Hirata, E., Yukinaga, H., Kamioka, Y., Arakawa, Y., Miyamoto, S., Okada, T., Sahai, E., and Matsuda, M. (2012). In vivo fluorescence resonance energy transfer imaging reveals differential activation of Rho-family GTPases in glioblastoma cell invasion. J. Cell Sci. 125, 858-868.
11. Hirata, E., Girotti, M.R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., and Sahai, E. (2015). Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell 27, 574-588.
12. Kefford, R.F., Maio, M., Arance, A. et al. (SMR 2013). Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicenter study. Cancer J. 20, 18-24, Abstract.
13. Komatsu, N., Aoki, K., Yamada, M., Yukinaga, H., Fujita, Y., Kamioka, Y., and Matsuda, M. (2011). Development of an optimized backbone of FRET biosensors for kinases and GTPases. Mol. Biol. Cell 22, 4647-4656.
14. Liu, L., and Duff, K. (2008). A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J. Vis. Exp. pii: 960.
15. Lok, E., Chung, A.S., Swanson, K.D., and Wong, E.T. (2014). Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid. Melanoma Res. 24, 120-130.
16. Long, G.V., Trefzer, U., Davies, M.A. et al. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095.
17. Manning, C., Jenkins, R.P., Hooper, S., Gerhardt, H., Marais, R., Adams, S., Adams, R.H., van Rheenen, J, and Sahai, E. (2013). Intravital imaging reveals conversion between distinct tumor vascular morphologies and localized vascular response to Sunitinib. IntraVital 2, 1-12.
18. Manning, C.S., Hooper, S., and Sahai, E.A. (2015). Intravital imaging of SRF and Notch signalling identifies a key role for EZH2 in invasive melanoma cells. Oncogene 34, 4320-4332.
19. McArthur, G.A., Chapman, P.B., Robert, C. et al. (2014). Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 15, 323-332.
20. Meier, S., Baumert, B.G., Maier, T., Wellis, G., Burg, G., Seifert, B., and Dummer, R. (2004). Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie 27, 145-149.
21. Menzies, A.M., Haydu, L.E., Carlino, M.S., Azer, M.W., Carr, P.J., Kefford, R.F., and Long, G.V. (2014). Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS ONE 9, e85004.
22. Mittapalli, R.K., Vaidhyanathan, S., Dudek, A.Z., and Elmquist, W.F. (2013). Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J. Pharmacol. Exp. Ther. 344, 655-664.
23. Niessner, H., Forschner, A., Klumpp, B. et al. (2013). Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med. 2, 76-85.
24. Papadatos-Pastos, D., Januszewski, A., and Dalgleish, A. (2013). Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS. Expert Rev. Anticancer Ther. 13, 559-567.
25. Protas, P.T., Holownia, A., Muszynska-Roslan, K., Wielgat, P., Krawczuk-Rybak, M., and Braszko, J.J. (2011). Cerebrospinal fluid IL-6, TNF-alpha and MCP-1 in children with acute lymphoblastic leukaemia during chemotherapy. Neuropediatrics 42, 254-256.
26. Pyonteck, S.M., Akkari, L., Schuhmacher, A.J. et al. (2013). CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264-1272.
27. Vaidhyanathan, S., Mittapalli, R.K., Sarkaria, J.N., and Elmquist, W.F. (2014). Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab. Dispos. 42, 1292-1300.
28. Wager, T.T., Villalobos, A., Verhoest, P.R., Hou, X., and Shaffer, C.L. (2011). Strategies to optimize the brain availability of central nervous system drug candidates. Expert Opin. Drug Discov. 6, 371-381.
29. Wilmott, J.S., Tembe, V., Howle, J.R., Sharma, R., Thompson, J.F., Rizos, H., Lo, R.S., Kefford, R.F., Scolyer, R.A., and Long, G.V. (2012). Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol. Cancer Ther. 11, 2704-2708.